Zusammenfassung
Hintergrund
Vor 20 Jahren beschrieben Hirota et al. die Expression einer Rezeptortyrosinkinase des Protoonkogens KIT durch einen besonderen Typ mesenchymaler Tumoren des Gastrointestinaltrakts: den gastrointestinalen Stromatumor (GIST). Seither ist die molekulare Diagnostik auch im Hinblick auf therapeutische Möglichkeiten fortgeschritten.
Fragestellung
Dieser Artikel zeichnet die Bedeutung der unterschiedlichen Tyrosinkinase(TK)-Rezeptor-Mutationen sowie die nachgeschalteten Signalwege bis in den Nukleus und ihre Relevanz für die Pathogenese und Therapie der GIST nach.
Material und Methode
Die gängige internationale Literatur wurde strukturiert zur Beantwortung bisher unklarer Fragen zusammengestellt.
Ergebnisse
Während KIT in unterschiedlichen Zellen exprimiert wird (Cajal-Zellen, hämatopoietischen Stammzellen, Melanozyten, Mastzellen und Keimzellen), entstehen GIST aus Cajal-Zellen (oder deren Vorläufern). Somit muß ein definierter zellulärer Kontext für die Entwicklung von GIST bestehen. Mikro-GIST zeigen bereits die Treibermutation im Tyrosinkinaserezeptor, entwickeln sich jedoch erst zu manifesten GIST bei hoher endogener Expression des Transkriptionsfaktors ETV1. Wie KIT- und PDGFRA-Mutationen schließen sich KRAS- und BRAF-Mutationen gegenseitig aus. KRAS- und BRAF-Mutationen können als nachgeschaltete Mutationen vorkommen. Wildtyp(WT)-GIST mit ihren Unterformen der Succinatdehydrogenase(SDH)-Defizienz sind jedoch gesondert zu betrachten. Ob sekundäre Mutationen unter therapeutischem Selektionsdruck neu entstehen oder – bereits vorhanden – selektiert werden, ist bisher unklar. Sekundäre Mutationen scheinen jedoch erst ab einem bestimmten Expressionsniveau Relevanz zu besitzen. Die Therapie fortgeschrittener GIST ist aufgrund der komplexen genomischen Evolution und der Entwicklung von Resistenzen erschwert.
Schlussfolgerungen
Trotz Ihrer Seltenheit bleiben GIST auch für komplexe Therapiesituationen Modelltumoren.
Abstract
Background
In 1998, Hirota et al. described the expression of a receptor tyrosine kinase of the protooncogene KIT by unique mesenchymal tumors of the gastrointestinal tract: gastrointestinal stromal tumors (GIST). Since then, molecular diagnostics have advanced, also in view of therapeutic options.
Aim
This article retraces the different tyrosine kinase receptor mutations as well as the downstream signaling pathways with subsequent nuclear events and their relevance for the prognosis and treatment of GIST.
Materials and methods
In order to answer previously unclear questions, the international literature is summarized in a structured manner.
Results
Whilst KIT is expressed in different cells (Cajal cells, hematopoietic stem cells, melanocytes, mast cells and germ cells), GIST only originate from Cajal cells (or their precursor cells); thus there should be a defined cellular context for the development of GIST. Micro-GIST already carry the driver mutation in the tyrosine kinase receptor, however, they only develop into manifest GIST if endogenous expression of the transcription factor ETV1 is high. Like KIT and PDGFRA mutations, KRAS and BRAF mutations are mutually exclusive. They can however occur as downstream mutations. Wild-type (WT) GIST with its subgroup “succinate dehydrogenase (SDH) deficiency” has to be viewed separately. Whether secondary mutations develop under therapy or are selected throughout therapy remains unclear. However, secondary mutations themselves seem to only take effect if a minimal expression level is exceeded. Therapeutic options in advanced GIST are limited because of their complex genetic evolution and the development of resistance.
Conclusions
Despite being rare, GIST remain model tumors even for complex therapeutic situations.
Literatur
Posner I, Engel M, Gazit A et al (1994) Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol 45:673–683
Ravegnini G, Sammarini G, Nannini M et al (2017) Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy 13:452–463
Cameron S (2018) Gastrointestinaler Stromatumor (GIST). Thieme, Stuttgart, S 119–133
Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c‑kit in human gastrointestinal stromal tumors. Science 279:577–580
Heinrich MC, Rubin BP, Longley BJ et al (2002) Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33:484–495
Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and Imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349
Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710
Sakurai S, Hasegawa T, Sakuma Y et al (2004) Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol 35:1223–1230
Martin-Broto J, Gutierrez A, Garcia-del-Muro X et al (2010) Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 21:1552–1557
Joensuu H, Wardelmann E, Sihto H et al (2017) Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant Imatinib: an exploratory analysis of a randomized clinical trial. Jama Oncol 3:602–609
Altimari A, deBiase D, deMaglio G et al (2013) 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. Onco Targets Ther 6:1057–1064
Cameron S, Savvoukidis T, Armbrust T et al (2009) Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors. Med Oncol. https://doi.org/10.1007/s12032-009-9193-0
Wardelmann E, Merkelbach-Bruse S, Pauls K et al (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with Imatinib mesylate. Clin Cancer Res 12:1743–1749
Wozniak A, Rutkowski P, Schoffski P et al (2014) Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST. Clin Cancer Res 20:6105–6116
Gajiwala KS, Wu JC, Christensen J et al (2009) KIT kinase mutants show unique mechanisms of drug resistance to Imatinib and Sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 106:1542–1547
Casali PG, LeCesne A, Velasco AP et al (2013) Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant Imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. J Clin Oncol 31(15_suppl):10500–10500. https://doi.org/10.1200/jco.2013.31.15_suppl.10500
DeMatteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant Imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104
DeMatteo RP, Ballman KV, Antonescu CR et al (2013) Long-term results of adjuvant Imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg 258:422–429
Joensuu H, Eriksson M, Sundby HK et al (2012) One vs three years of adjuvant Imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307:1265–1272
Kang Y‑K, Ryu M‑H, Ryoo B‑Y et al (2013) Randomized phase III trial of Imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and Sunitinib (SU): RIGHT study. J Clin Oncol 31(18_suppl):10502. https://doi.org/10.1200/jco.2013.31.18_suppl.lba10502
Heinrich MC, Owzar K, Corless CL et al (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of Imatinib mesylate for treatment of advanced gastrointestinal stromal tumor. J Clin Oncol 26:5360–5367 (CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group)
Kunstlinger H, Huss S, Merkelbach-Bruse S et al (2013) Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Am J Surg Pathol 37:1648–1659
Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of Sunitinib in patients with advanced gastrointestinal stromal tumour after failure of Imatinib: a randomised controlled trial. Lancet 368:1329–1338
Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of Sunitinib in Imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352–5359
Agaimy A, Bauer S, Beham A et al (2015) Gastrointestinal Stromal Tumours (GIST) – development in pathology, surgery and medical therapy. Z Gastroenterol 53:235–243
Heinrich MC, Marino-Enriquez A, Presnell A et al (2012) Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther 11:1770–1780
Kindler HL, Campbell NP, Wroblewski K et al (2011) Sorafenib (SOR) in patients (pts) with Imatinib (IM) and Sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. J Clin Oncol 29(15_suppl):10009–10009. https://doi.org/10.1200/jco.2011.29.15_suppl.10009
Rini BI (2007) Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 13:1098–1106
Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of Regorafenib for advanced gastrointestinal stromal tumours after failure of Imatinib and Sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302
Garner AP, Gozgit JM, Anjum R et al (2014) Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res 20:5745–5755
Bauer S, Joensuu H (2015) Emerging agents for the treatment of advanced, Imatinib-resistant gastrointestinal Stromal tumors: current status and future directions. Drugs 75:1323–1334
Blay JY, Domont J, Cropet C et al (2015) LBA45A randomized multicentre phase II study of Pazopanib plus best supportive care (BSC) vs. BSC alone in metastatic gastrointestinal stromal tumors (GIST) resistant to Imatinib and Sunitinib. Ann Oncol 25(suppl 4):v41–v1. https://doi.org/10.1093/annonc/mdu438.57
Montemurro M, Schoffski P, Reichardt P et al (2009) Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both Imatinib and Sunitinib. Eur J Cancer 45:2293–2297
Mir O, Cropet C, Toulmonde M et al (2016) Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to Imatinib and Sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 17:632–641
Trent JC, Wathen K, von Mehren M et al (2011) A phase II study of dasatinib for patients with Imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 29(15_suppl):10006–10006. https://doi.org/10.1200/jco.2011.29.15_suppl.10006
Adenis A, Blay JY, Bui-Nguyen B et al (2014) Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of Imatinib: a randomized controlled open-label trial. Ann Oncol 25:1762–1769
Miranda C, Nucifora M, Molinari F et al (2012) KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18:1769–1776
Agaimy A, Terracciano LM, Dirnhofer S et al (2009) V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 62:613–616
Agaram NP, Wong GC, Guo T et al (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47:853–859
Huss S, Pasternack H, Ihle MA et al (2017) Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. Hum Pathol 62:206–214
Falchook GS, Trent JC, Heinrich MC et al (2013) BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor Dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 4:310–315
ClinicalTrials.gov https://clinicaltrials.gov. Zugegriffen: 16. Juli 2018
Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255
Andersson J, Sihto H, Meis-Kindblom JM et al (2005) NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 29:1170–1176
Miettinen M, Lasota J (2014) Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) – A review. Int J Biochem Cell Biol 53:514–519
Soni S, Padwad YS (2017) HIF-1 in cancer therapy: two decade long story of a transcription factor. Acta Oncol 56:503–515
Kuroda D, Kurashige J, Iwatsuki M et al (2016) The clinical significance of GLUT1 expression in gastrointestinal stromal tumor. Cancer Res 76(suppl. 14):38–38. https://doi.org/10.1158/1538-7445.am2016-38
Belinsky MG, Rink L, Flieder DB et al (2013) Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer 52:214–224
Lasota J, Wang Z, Kim SY et al (2013) Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol 37:114–119
Aaronson DS, Horvath CM (2002) A road map for those who don’t know JAK-STAT. Science 296:1653–1655
Haller F, Zhang DJ, Lobke C et al (2010) Multilayer analysis of signal transduction and cell cycle control in GIST. Pathologe 31(Suppl 2):134–137. https://doi.org/10.1007/s00292-010-1339-5 (Multilayer-Analyse der Signaltransduktion und Zellzykluskontrolle in GIST)
Judson I, Scurr M, Gardner K et al (2014) Phase II study of Cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res 20:3603–3612
Joensuu H, Blay JY, Comandone A et al (2017) Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to Imatinib. Br J Cancer 117:1278–1285
Zeng S, Seifert AM, Zhang JQ et al (2017) Wnt/beta-catenin signaling contributes to tumor malignancy and is targetable in gastrointestinal Stromal tumor. Mol Cancer Ther 16:1954–1966
Haikarainen T, Krauss S, Lehtio L (2014) Tankyrases: structure, function and therapeutic implications in cancer. Curr Pharm Des 20:6472–6488
Bertucci F, Finetti P, deNonneville A et al (2018) „Wnt/beta-Catenin in GIST“-Letter. Mol Cancer Ther 17:327–328
Chi P, Chen Y, Zhang L et al (2010) ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467:849–853
Zeng S, Seifert AM, Zhang JQ et al (2017) ETV4 collaborates with Wnt/beta-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor. Oncotarget 8:114195–114209
Pinto F, Campanella NC, Abrahao-Machado LF et al (2016) The embryonic Brachyury transcription factor is a novel biomarker of GIST aggressiveness and poor survival. Gastric Cancer 19:651–659
Kurrey NK, Jalgaonkar SP, Joglekar AV et al (2009) Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27:2059–2068
Hamilton DH, David JM, Dominguez C et al (2017) Development of cancer vaccines targeting Brachyury, a transcription factor associated with tumor epithelial-Mesenchymal transition. Cells Tissues Organs (Print) 203:128–138
Cameron S, Gieselmann M, Blaschke M, al Ret (2014) Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). Int J Clin Exp Pathol 7:3563–3579
Rusakiewicz S, Semeraro M, Sarabi M et al (2013) Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 73:3499–3510
Wang H, Cheng F, Cuenca A et al (2005) Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T‑cell tolerance. Blood 105:1135–1143
Reilley MJ, Bailey A, Subbiah V et al (2017) Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35
D’Angelo SP, Shoushtari AN, Keohan ML et al (2017) Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of Dasatinib plus Ipilimumab. Clin Cancer Res 23:2972–2980
Polier G, Neumann J, Thuaud F et al (2012) The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem Biol 19:1093–1104
Bauer S, Yu LK, Demetri GD et al (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66:9153–9161
Wagner AJ, Chugh R, Rosen LS et al (2013) A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res 19:6020–6029
Demetri GD, Heinrich MC, Chmielowski B et al (2011) An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients with metastatic and/or unresectable GIST. J Clin Oncol 29(suppl. 15):10011–10011. https://doi.org/10.1200/jco.2011.29.15_suppl.10011
Dickson MA, Okuno SH, Keohan ML et al (2013) Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol 24:252–257
Cameron S, Beham A, Schildhaus HU (2017) Current standard and future perspectives in the treatment of gastrointestinal Stromal tumors. Digestion 95:262–268
Bauer S, Hilger RA, Muhlenberg T et al (2014) Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer 110:1155–1162
Mol CD, Dougan DR, Schneider TR et al (2004) Structural basis for the autoinhibition and STI-571 inhibition of c‑Kit tyrosine kinase. J Biol Chem 279:31655–31663
Janku F, George S, Razak A et al (2016) DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study. Eur J Cancer 69(suppl 1):S4. https://doi.org/10.1016/s0959-8049(16)32613-2
Wang Y, Marino-Enriquez A, Bennett RR et al (2014) Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet 46:601–606
Schaefer IM, Wang Y, Liang CW et al (2017) MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun 8:14674. https://doi.org/10.1038/ncomms14674
Danksagung
Ich danke Herrn Professor Abbas Agaimy, Pathologie Universität Erlangen, für das Korrekturlesen des Manuskripts.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
S. Cameron gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Redaktion
V. Ellenrieder, Göttingen
P. Michl, Halle (Saale)
Rights and permissions
About this article
Cite this article
Cameron, S. Gastrointestinale Stromatumoren. Gastroenterologe 13, 336–348 (2018). https://doi.org/10.1007/s11377-018-0276-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11377-018-0276-3